Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-05-23
1996-12-24
Shah, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514265, 544268, 544264, 544265, A61K 3152
Patent
active
055873782
ABSTRACT:
Methods for the treatment of Parkinson's disease comprising administering to a patient an agent which contains, as an active ingredient, a xanthine derivative or a pharmaceutically acceptable salt thereof. The xanthine derivative is represented by the formula: ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 are independently hydrogen, lower alkyl, lower alkenyl, or lower alkynyl; and R.sup.4 is cycloalkyl, --(CH.sub.2).sub.n --R.sup.5, wherein R.sup.5 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group; and n is an integer of 0 to 4, or ##STR2## wherein Y.sup.1 and Y.sup.2 represent independently hydrogen, halogen, or lower alkyl; and Z is substituted or unsubstituted aryl, ##STR3## wherein R.sup.6 is hydrogen, hydroxy, lower alkyl, lower alkoxy, halogen, nitro, or amino; and m is an integer of 1 to 4, or a substituted or unsubstituted heterocyclic group; and X.sup.1 and X.sup.2 are independently O or S.
REFERENCES:
patent: 2729642 (1956-01-01), Burgison
patent: 3624215 (1971-11-01), Stein et al.
patent: 3624216 (1971-11-01), Stein et al.
patent: 3641010 (1972-02-01), Schweiss et al.
patent: 3900474 (1975-08-01), Ginger et al.
patent: 4452788 (1984-06-01), Bristol et al.
patent: 4548820 (1985-10-01), Regnier et al.
patent: 4612315 (1986-09-01), Jacobson et al.
patent: 4696932 (1987-09-01), Jacobson et al.
patent: 4755517 (1988-07-01), Bruns et al.
patent: 4879296 (1989-11-01), Daluge et al.
patent: 4968672 (1990-11-01), Jacobson et al.
patent: 4981857 (1991-01-01), Daluge et al.
patent: 5098996 (1992-03-01), Jacobson et al.
patent: 5173491 (1992-12-01), Kamoun et al.
patent: 5175291 (1992-12-01), Kufner-Muhl
patent: 5248770 (1993-09-01), Jacobson et al.
Cecil; Text Book of Medicine, 19th Edition W. B. Saunders Co., 1992 p. 2077.
Rennie., Scientific American, Jun. 1992 p. 20 (The Mice That Missed).
Ossowska et al., Europ. J. Pharmacol. 182, (1990) 327-334
Erickson R. H. et al. "1,3,8-Trisubstituted Xanthines. Effects of Substitution Pattern upon Adenosine Receptor A.sub.1 /A.sub.2 Affinity". J. Med. Chem., 34, col. 1431-1435 (1991).
Kaupp, G. und Ringer, E. "Multifunktionelle Photoaddition von Stilben an Coffeinderivate und Benzothiazole." Chem. Ber., 119, col. 1525-1539 (1986).
Lugovkin, B. P. "Condensation of Isocaffeine-8-carboxaldehyde with Alkyl Iodides of Heterocyclic Bases." Chem. Abst., 60, col. 1741-1742 (1964).
Heikkila, et al. "Dopaminegeric Neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice", Science 224: 1451-1453 (1984).
Langston, et al. "Chronic Parkinsonism in humans due to a product of Meperidine-analog synthesis", Science 219: 979-980 (1983).
Jiang, et al. "Adenosine receptor antagonists potentiate dopamine receptor agonist -induced rotational behavior in 6-hydoxydopamine-lesioned rats", Brain Res. 613:347-351 (1993).
Jacobson, K. A. et al. "Structure-Activity Relationships of 8-Styrylxanthines as A.sub.2 -Selective Adenosine Antagonists," J. Med. Chem. 36: 1333-1342, 1993.
Ichikawa Shunji
Ishii Akio
Koike Nobuaki
Nakamura Joji
Nonaka Hiromi
Kyowa Hakko Kogyo Co. Ltd.
Shah Mukund J.
Sripada Pavanaram K.
LandOfFree
Therapeutic agent for Parkinson's disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic agent for Parkinson's disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic agent for Parkinson's disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1178695